Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Shoichiro Ogawa Tapped as Alcon Pharma Japan Chief
Alcon Pharma appointed Shoichiro Ogawa as its president effective October 1, the company, which was created in April through the integration of Novartis Pharma’s ophthalmology division and Alcon Japan’s pharma unit, said on October 2. Mr Ogawa, 48, assumed the…
To read the full story
Related Article
- Alcon Pharma to Be Integrated into Novartis Japan in April
March 6, 2019
- Alcon Pharma Kicks Off Operations
April 3, 2017
BUSINESS
- Padcev-Keytruda Gets CHMP Nod for Cisplatin-Ineligible Bladder Cancer
May 25, 2026
- Japan Market Hits Record 11.8 Trillion Yen in FY2025, Keytruda Keeps Title: IQVIA
May 22, 2026
- Kissei Drops Call to Halt New Tavneos Use after Blue Letter Action
May 22, 2026
- Servier’s Voranigo Seen as Potential Standard of Care for Glioma: Expert
May 22, 2026
- Ultragenyx’s LC-FAOD Therapy Dojolvi Now Available in Japan
May 22, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…